These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 2506219)

  • 21. Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins.
    Silverberg KM; Burns WN; Olive DL; Riehl RM; Schenken RS
    J Clin Endocrinol Metab; 1991 Oct; 73(4):797-803. PubMed ID: 1909704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The synergistic effects of clomiphene citrate and human menopausal gonadotrophin in the folliculogenesis of stimulated cycles as assessed by the gonadotrophin-releasing hormone antagonist Nal-Glu.
    Cassidenti DL; Paulson RJ; Lobo RA; Sauer MV
    Hum Reprod; 1992 Mar; 7(3):344-8. PubMed ID: 1587939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrauterine insemination: effect of the temporal relationship between the luteinizing hormone surge, human chorionic gonadotrophin administration and insemination on pregnancy rates.
    Fuh KW; Wang X; Tai A; Wong I; Norman RJ
    Hum Reprod; 1997 Oct; 12(10):2162-6. PubMed ID: 9402275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum and follicular fluid (FF) estradiol (E2) levels in ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT) conception cycles after pituitary suppression.
    Leya J; Molo MW; Olson D; Radwanska E
    J In Vitro Fert Embryo Transf; 1991 Jun; 8(3):137-40. PubMed ID: 1919258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of exogenous human chorionic gonadotropin cycles with spontaneous luteinizing hormone surges on the outcome of in vitro fertilization.
    Wang TA; Armant DR; Taymor ML; Seibel MM
    Fertil Steril; 1987 Oct; 48(4):613-6. PubMed ID: 3115837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
    Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
    Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix).
    Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Siebert-Weigel M; Diedrich K; Van Steirteghem AC; Devroey P
    Hum Reprod; 1996 Oct; 11(10):2114-8. PubMed ID: 8943511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
    Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
    Fertil Steril; 1991 Nov; 56(5):923-7. PubMed ID: 1936328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pituitary down-regulation using leuprolide for the intensive ovulation management of poor prognosis patients having in vitro fertilization (IVF)-related treatments.
    Cummins JM; Yovich JM; Edirisinghe WR; Yovich JL
    J In Vitro Fert Embryo Transf; 1989 Dec; 6(6):345-52. PubMed ID: 2517507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blunted LH surge after HCG administration in cycles superovulated for in-vitro fertilization.
    Hamori M; Stuckensen JA; Rumpf D; Kniewald T; Kniewald A; Marquez M
    Hum Reprod; 1989 May; 4(4):392-5. PubMed ID: 2501335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Premature luteinization is not eliminated by pituitary desensitization with leuprolide acetate in women undergoing gonadotrophin stimulation who demonstrated premature luteinization in a prior gonadotrophin-only cycle.
    Hofmann GE; Bergh PA; Guzman I; Masuku S; Navot D
    Hum Reprod; 1993 May; 8(5):695-8. PubMed ID: 8314961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progesterone response to exogenous gonadotropins after suppression with leuprolide acetate in gamete intrafallopian transfer.
    Riemann DC; Schoolcraft WB; Sinton EB
    J Reprod Med; 1991 Mar; 36(3):190-4. PubMed ID: 1903164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins.
    Wildt L; Diedrich K; van der Ven H; al Hasani S; Hübner H; Klasen R
    Hum Reprod; 1986 Jan; 1(1):15-9. PubMed ID: 2971082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro fertilization: determination of follicular maturation for timing of human chorionic gonadotropin administration.
    Casper RF; Armstrong DT; Brown SE; Daniel SA; Yuzpe AA; Erskine H
    Fertil Steril; 1987 Feb; 47(2):345-9. PubMed ID: 3102289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between prolactin, gonadotrophins and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonists and human menopausal gonadotrophin for an in-vitro fertilization programme.
    Kamel MA; Zabel G; Bernart W; Neulen J; Breckwoldt M
    Hum Reprod; 1994 Oct; 9(10):1803-6. PubMed ID: 7844206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian response and pregnancy rates in in vitro fertilization, gamete intrafallopian transfer, and in vivo fertilization therapies after combined gonadotropin-releasing hormone agonist/human menopausal gonadotropin stimulation.
    Lindner C; Braendle W; Lichtenberg V; Köhler S; Bettendorf G
    Gynecol Obstet Invest; 1990; 29(2):140-4. PubMed ID: 2139861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin-releasing hormone agonist for ovulation induction.
    Yding Andersen C; Westergaard LG; Figenschau Y; Bertheussen K; Forsdahl F
    Hum Reprod; 1993 Jun; 8(6):840-3. PubMed ID: 8345072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated luteinizing hormone on the day of human chorionic gonadotropin administration does not reduce cycle fecundity in a low-dose flare-up in vitro fertilization protocol.
    Lincoln SR; Long CA; Whitworth NS; Sopelak VM; Cowan BD
    Fertil Steril; 1995 Mar; 63(3):563-5. PubMed ID: 7851587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-finding study of Leuplin depot for prevention of premature luteinizing hormone surge during controlled ovarian stimulation: a pilot study in intrauterine insemination treatment.
    Chen HJ; Lin YH; Huang MZ; Seow KM; Huang LW; Hsieh BC; Tzeng CR; Hwang JL
    Taiwan J Obstet Gynecol; 2016 Apr; 55(2):235-8. PubMed ID: 27125407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.